Cytoreductive treatment for essential thrombocythemia in Colombia. Panoramic review of the evidence

Tratamiento citorreductor disponible en Colombia para la trombocitemia esencial. Revisión panorámica de la evidencia

Published 2021-10-01

Open | Download
PDF (Spanish) FLIP
Issue
Vol. 8 No. 1 (2021): Enero-Junio
Section
Revisiones
How to Cite
Cytoreductive treatment for essential thrombocythemia in Colombia. Panoramic review of the evidence.
Rev. colomb. hematol. oncol. [Internet]. 2021 Oct. 1 [cited 2025 Jan. 3];8(1):76-89. Disponible en: https://doi.org/10.51643/22562915.335
DOI

https://doi.org/10.51643/22562915.335
Dimensions
PlumX
license
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Virginia Abello Polo
Clínica del Country, Bogotá
    https://orcid.org/0000-0001-6507-4041
    Carmen Rosales Oliveros
    SOHEC, Valledupar
      https://orcid.org/0000-0002-6099-3492
      Kenny Mauricio Gálvez Cárdenas
      Hospital Pablo Tobón Uribe, Medellín
        José Domingo Saavedra
        Clínica Vida - Sede Poblado, Medellín
          Juan Guillermo Duque Ortega
          Instituto Neurum
            Show authors biography

            Virginia Abello Polo,

            Médica Hematóloga

            Carmen Rosales Oliveros,

            Médica Hematóloga

            Kenny Mauricio Gálvez Cárdenas ,

            Médico Hematólogo

            José Domingo Saavedra,

            Médico Hematólogo

            Juan Guillermo Duque Ortega,

            Médico Hematólogo

            Essential thrombocythemia (ET) is a BCR-ABL negative chronic myeloproliferative neoplasm, characterized by excessive production of clonal platelets. The worldwide prevalence varies, being approximately 38 to 57 per 100,000. Treatment of ET is aimed at reducing the risk of thrombosis or bleeding complications. Aim: The purpose of this panoramic review is to evaluate the current evidence on the cytoreductive treatment of essential thrombocythemia available in Colombia. Methods: A structured literature search was carried out regarding the effectiveness and safety of cytoreductive treatments in patients with essential thrombocythemia. Based on the research question with a PICO structure, the inclusion criteria were defined: Patients with essential thrombocythemia, under management with Anagrelide and/or Hydroxyurea. Studies from systematic reviews, meta-analyses, randomized clinical trials were included. Results: A search was carried out in MEDLINE, EMBASE, LILACS, Cochrane Database of Systematic Reviews, which yielded 119 references, of which 4 studies were included, which met the characteristics of the population, intervention, and comparator. Conclusions: Cytoreductive therapy is essential for the management of Essential Thrombocythemia. Evidence suggests that both Hydroxyurea and Anangrelide are agents that provide similar protection against clinically significant thrombo-hemorrhagic events.

            Article visits 1937 | PDF visits 2343

            1. Alvarez-Larrán A, Cervantes F, Besses C. Tratamiento de la trombocitemia esencial. Medicina Clínica [Internet]. 2013;141(6):260-4. Disponible en: http://www.sciencedirect.com/science/article/pii/S0025775313000821
            2. Aruch D, Mascarenhas J. Contemporary approach to essential thrombocythemia and polycythemia vera. Curr Opin Hematol. [Internet] 2016;23(2):150-60. Disponible en: https://journals.lww.com/co-hematology/Abstract/2016/03000/Contemporary_approach_to_essential_thrombocythemia.12.aspx
            3. Hong J, Lee JH, Byun JM, Lee JY, Koh Y, Shin D-Y, et al. Risk of disease transformation and second primary solid tumors in patients with myeloproliferative neoplasms. Blood Adv [Internet]. 2019;3(22):3700-8. Disponible en: https://ashpublications.org/bloodadvances/article/3/22/3700/428870/Risk-of-disease-transformation-and-second-primary
            4. Beer PA. The pathogenesis of essential thrombocythemia. Curr Opin Hematol. 2011;18(5):323-9. Disponible en: https://journals.lww.com/co-hematology/Abstract/2011/09000/The_pathogenesis_of_essential_thrombocythemia.4.aspx
            5. Gangat N, Wolanskyj AP, McClure RF, Li C-Y, Schwager S, Wu W, et al. Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients. Leukemia. 2007;21(2):270-6. Disponible en: https://www.nature.com/articles/2404500
            6. Tefferi A, Barbui T. Essential Thrombocythemia and Polycythemia Vera: Focus on Clinical Practice. Mayo Clinic Proceedings [Internet]. 2015;90(9):1283-93. Disponible en: http://www.sciencedirect.com/science/article/pii/S0025619615004656
            7. Yogarajah M, Tefferi A. Leukemic Transformation in Myeloproliferative Neoplasms: A Literature Review on Risk, Characteristics, and Outcome. Mayo Clin Proc. 2017;92(7):1118-28. DOI: 10.1016/j.mayocp.2017.05.010
            8. Angona A, Alvarez-Larrán A, Bellosillo B, Martínez-Avilés L, Garcia-Pallarols F, Longarón R, et al. Trombocitemia esencial: características iniciales y factores de riesgo de supervivencia y trombosis en una serie de 214 pacientes. Medicina Clínica [Internet]. 2015;144(6):247-53. Disponible en: http://www.sciencedirect.com/science/article/pii/S0025775314005776
            9. Shallis RM, Wang R, Davidoff A, Ma X, Podoltsev NA, Zeidan AM. Epidemiology of the classical myeloproliferative neoplasms: The four corners of an expansive and complex map. Blood Reviews [Internet]. 2020;42:100706. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S0268960X20300564
            10. Mangaonkar AA, Hoversten KP, Gangat N. Prognostic risk model for patients with high-risk polycythemia vera and essential thrombocythemia. Expert Rev Hematol. [Internet]. 2018;11(3):247-52. Disponible en: https://www.tandfonline.com/doi/abs/10.1080/17474086.2018.1426455?journalCode=ierr20
            11. Abello V, Quintero G, Espinosa D, Solano MH, Casas CP, Saavedra D, et al. Descripción de las caracteristicas clínicas de las neoplasias mieloproliferativas crónicas (NMPC). Primer informe del registro colombiano de NMPC. Acta Médica Colombiana. [Internet]. 2017;42(1):35-41. Disponible en: http://www.scielo.org.co/scielo.php?script=sci_abstract&pid=S0120-24482017000100035&lng=en&nrm=iso&tlng=es
            12. Ashorobi D, Gohari P. Essential Thrombocytosis (Essential Thrombocythemia, ET). En: StatPearls. [Internet]. Treasure Island (FL): StatPearls Publishing; 2020. Disponible en: http://www.ncbi.nlm.nih.gov/books/NBK539709/
            13. Mora B, Passamonti F. Developments in diagnosis and treatment of essential thrombocythemia. Expert Rev Hematol. [Internet]. 2019;12(3):159-71. DOI:10.1080/17474086.2019.1585239
            14. Mesa RA, Niblack J, Wadleigh M, Verstovsek S, Camoriano J, Barnes S, et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer. [Internet]. 2007;109(1):68-76. Disponible: https://acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/cncr.22365
            15. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. [Internet]. 2016;127(20):2391-405. Disponible en: https://ashpublications.org/blood/article/127/20/2391/35255/The-2016-revision-to-the-World-Health-Organization
            16. Vannucchi AM, Barbui T, Cervantes F, Harrison C, Kiladjian J-J, Kröger N, et al. Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. [Internet]. 2015;26 Suppl 5:85-99. Disponible en: https://www.esmo.org/guidelines/haematological-malignancies/philadelphia-chromosome-negative-chronic-myeloproliferative-neoplasms
            17. Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R, et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia. [Internet]. 2018;32(5):1057-69. Disponible en: https://www.nature.com/articles/s41375-018-0077-1
            18. Besses C, CF, Vannucchi AM, Buxhofer-Ausch V, De Stefano V, Betti S, Rambaldi A, et al. Neoplasias Mieloproliferativas Crónicas Filadelfia Negativas Manual de Recomendaciones GEMFIN Segunda Edición, 2016. Blood Cancer J. 2015;5(11):e369. Disponible en: http://www.sehh.es/images/stories/recursos/2017/09/08/DOCGUIAGEMFINDEF2_octubre_infinitum.pdf.
            19. Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. [Internet]. 2005;353(1):33-45. Disponible en: https://www.nejm.org/doi/10.1056/NEJMoa043800?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200www.ncbi.nlm.nih.gov
            20. Gisslinger H, Gotic M, Holowiecki J, Penka M, Thiele J, Kvasnicka H-M, et al. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood. [Internet]. 2013;121(10):1720-8. Disponible en:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3591796/
            21. Birgegård G, Besses C, Griesshammer M, Gugliotta L, Harrison CN, Hamdani M, et al. Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the Evaluation of Anagrelide Efficacy and Long-term Safety study. Haematologica. [Internet]. 2018;103(1):51-60. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5777190/
            22. Martínez-Sellés M, Datino T, Figueiras-Graillet L, Gama JG, Jones C, Franklin R, et al. Cardiovascular Safety of Anagrelide in Healthy Subjects: Effects of Caffeine and Food Intake on Pharmacokinetics and Adverse Reactions. Clinical Drug Investigation. [Internet]. 2013;33(1):45-54. Disponible en:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3586167/
            23. Mesa RA, Miller CB, Thyne M, Mangan J, Goldberger S, Fazal S, et al. Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: Findings from the MPN Landmark survey. Cancer. [Internet]. 2017;123(3):449-58. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5297986/
            24. Barosi G, Birgegard G, Finazzi G, Griesshammer M, Harrison C, Hasselbalch HC, et al. Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood [Internet]. 2009;113(20):4829-33. Disponible en: https://ashpublications.org/blood/article/113/20/4829/116483/Response-criteria-for-essential-thrombocythemia
            25. Gerds A, Gotlib J. Recently updated NCCN Clinical Practice Guidelines in OncologyTM National Comprehensive Cancer Network. [Internet]. Disponible en: https://www.nccn.org/professionals/physician_gls/recently_updated.aspx
            26. Chuzi S, Stein BL. Essential thrombocythemia: a review of the clinical features, diagnostic challenges, and treatment modalities in the era of molecular discovery. Leuk Lymphoma. [Internet]. 2017;58(12):2786-98. Disponible en:https://www.tandfonline.com/doi/abs/10.1080/10428194.2017.1312371?journalCode=ilal20
            27. Gunawan A, Harrington P, Garcia-Curto N, McLornan D, Radia D, Harrison C. Ruxolitinib for the Treatment of Essential Thrombocythemia. HemaSphere [Internet]. 2018;2(4):e56. Disponible en: https://journals.lww.com/hemasphere/Fulltext/2018/08000/Ruxolitinib_for_the_Treatment_of_Essential.6.aspx
            28. Alerts. Drug Office [Internet]. Canada: Summary Safety Review; 2020. Disponible en: https://www.drugoffice.gov.hk/eps/news/showNews/Canada%3A+Summary+Safety+Review+-+Xeljanz+and+Xeljanz+XR+%28tofacitinib%29+and+Jakavi+%28ruxolitinib%29+-+Janus+Kinase+%28JAK%29+inhibitors+-+Assessing+the+Potentia/pharmaceutical_trade/2020-06-19/en/40590.html
            29. Vannucchi AM, Guglielmelli P, Tefferi A. Polycythemia vera and essential thrombocythemia: algorithmic approach. Curr Opin Hematol. [Internet]. 2018;25(2):112-9. Disponible en: https://journals.lww.com/co-hematology/Abstract/2018/03000/Polycythemia_vera_and_essential_thrombocythemia_.9.aspx
            30. Godfrey AL, Campbell PJ, MacLean C, Buck G, Cook J, Temple J, et al. Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk Features. J Clin Oncol. [Internet]. 2018;36(34):3361-9. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6269131/
            31. Gwilt PR, Tracewell WG. Pharmacokinetics and Pharmacodynamics of Hydroxyurea: Clinical Pharmacokinetics. [Internet].1998;34(5):347-58. Disponible en: https://link.springer.com/article/10.2165/00003088-199834050-00002
            32. Gugliotta L, Besses C, Griesshammer M, Harrison C, Kiladjian J-J, Coll R, et al. Combination therapy of hydroxycarbamide with anagrelide in patients with essential thrombocythemia in the evaluation of Xagrid(R) efficacy and long-term safety study. Haematologica. [Internet]. 2014;99(4):679-87. Disponible en : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3971078/
            33. Christoforidou A, Pantelidou D, Anastasiadis A, Goutzouvelidis A, Margaritis D, Kotsianidis I, et al. Hydroxyurea and Anagrelide Combination Therapy in Patients with Chronic Myeloproliferative Diseases Resistant or Intolerant to Monotherapy. Acta Haematol. [Internet]. 2008;120(4):195-8. Disponible en: https://www.karger.com/Article/Abstract/189381
            34. Besses C Cervantes F, Vannucchi AM, Buxhofer-Ausch V, De Stefano V, Betti S, Rambaldi A, et al. Neoplasias Mieloproliferativas Crónicas Filadelfia Negativas Manual de Recomendaciones GEMFIN Segunda Edición, 2016. Blood Cancer J [Internet]. 2015;5(11):e369. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4670947/
            35. Hernández-Boluda J-C, Alvarez-Larrán A, Gómez M, Angona A, Amat P, Bellosillo B, et al. Clinical evaluation of the European LeukaemiaNet criteria for clinicohaematological response and resistance/intolerance to hydroxycarbamide in essential thrombocythaemia. British Journal of Haematology. [Internet]. 2011;152(1):81-8. Disponible en: https://onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2141.2010.08430.x
            36. Wagstaff AJ, Keating GM. A Review of its Use in the Management of Essential Thrombocythaemia. Drugs. [Internet]. 2006;66(1):111-131. Disponible en: https://link.springer.com/article/10.2165/00003495-200666010-00006
            37. Spencer CM, Brogden RN. Anagrelide: A Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Potential in the Treatment of Thrombocythaemia. Drugs. [Internet], 1994;47(5):809-22. Disponible en:https://link.springer.com/article/10.2165%2F00003495-199447050-00007

            Information

            Directories and indexers
            Google Scholar profile

            QR code

            Keywords

            Most read in the last 30 days

            Current Issue

            Sistema OJS 3.4.0.7 - Metabiblioteca |